H.R. 7877

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7877 Introduced in House (IH)]

<DOC>

119th CONGRESS
2d Session
H. R. 7877

To require the Secretary of Health and Human Services to establish a 
demonstration program to test mandatory coverage of treatment for wound 
care for epidermolysis bullosa under the Medicaid program.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

March 9, 2026

Mr. Landsman introduced the following bill; which was referred to the 
Committee on Energy and Commerce

_______________________________________________________________________

A BILL

To require the Secretary of Health and Human Services to establish a 
demonstration program to test mandatory coverage of treatment for wound 
care for epidermolysis bullosa under the Medicaid program.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Shane DiGiovanna Act''.

SEC. 2. DEMONSTRATION PROGRAM TO TEST MANDATORY COVERAGE OF TREATMENT 
FOR WOUND CARE FOR EPIDERMOLYSIS BULLOSA UNDER THE 
MEDICAID PROGRAM.

(a) In General.--Beginning not later than 1 year after the date of 
the enactment of this Act, the Secretary of Health and Human Services 
(in this section referred to as the ``Secretary'') shall conduct a 2-
year demonstration program under which items and services specified in 
subsection (b) furnished for the treatment of epidermolysis bullosa are 
required to be included as medical assistance under a State plan (or 
waiver of such plan) under title XIX of the Social Security Act (42 
U.S.C. 1396 et seq.) for individuals described in section 
1902(a)(10)(A)(i) of such Act (42 U.S.C. 1396a(a)(10)(A)(i)).
(b) Specified Items and Services.--For purposes of subsection (a), 
the items and services specified in this subsection are over-the-
counter antihistamines, acetaminophen, nonsteroidal anti-inflammatory 
drugs, antiseptics, zinc oxide, antibiotic ointments, and necessary 
wound care supplies, including wound care dressings (inclusive of 
primary and secondary dressings), gauze, and bandage retainers.
(c) Scope of Demonstration.--The Secretary shall conduct the 
demonstration program described in subsection (a) on a nationwide 
basis.
(d) Study.--Not later than 1 year after the end of the 
demonstration program described in subsection (a), the Secretary shall 
submit to Congress a report on such program. Such report shall include 
the following:
(1) An evaluation of the effect of such program on 
expenditures for treatment of individuals with epidermolysis 
bullosa under the Medicaid program (taking into account any 
such treatment avoided due to such program).
(2) An analysis of health outcomes for such individuals 
compared to such outcomes before such program.
(3) Any recommendations relating to how to prevent 
hospitalizations relating to epidermolysis bullosa.
<all>